{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:22:44Z","timestamp":1785522164433,"version":"3.56.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03629-w","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:40:02Z","timestamp":1779529202000},"page":"3568-3586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Luis","family":"Le\u00f3n-Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"S\u00e1nchez-Gastaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rabeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Auliac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian T.","family":"Rieke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Iranzo Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong Ivy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-7633","authenticated-orcid":false,"given":"Grace","family":"Segall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"3629_CR1","unstructured":"International Agency for Research on Cancer and World Health Organization GLOBOCAN 2022: Lung. 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed 1 Oct 2025."},{"issue":"3","key":"3629_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3629_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288\u2013300.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"3629_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","volume":"12","author":"A Friedlaender","year":"2024","unstructured":"Friedlaender A, Perol M, Banna GL, Parikh K, Addeo A. Oncogenic alterations in advanced NSCLC: a molecular super-highway. Biomark Res. 2024;12(1):24.","journal-title":"Biomark Res"},{"issue":"6","key":"3629_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611\u201325.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3629_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.32604\/oncologie.2022.027545","volume":"24","author":"J Shi","year":"2022","unstructured":"Shi J, Chen Y, Peng C, et al. Advances in targeted therapy against driver mutations and epigenetic alterations in non-small cell lung cancer. Oncologie. 2022;24(4):613\u201348.","journal-title":"Oncologie"},{"key":"3629_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104554","volume":"205","author":"L Liguori","year":"2025","unstructured":"Liguori L, Salomone F, Viggiano A, et al. KRAS mutations in advanced non-small cell lung cancer: from biology to novel therapeutic strategies. Crit Rev Oncol Hematol. 2025;205:104554.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"3629_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357.","journal-title":"Ann Oncol"},{"key":"3629_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.992636","volume":"12","author":"A Verrienti","year":"2022","unstructured":"Verrienti A, Grani G, Sponziello M, et al. Precision oncology for RET-related tumors. Front Oncol. 2022;12:992636.","journal-title":"Front Oncol"},{"issue":"10","key":"3629_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","volume":"13","author":"A Drilon","year":"2018","unstructured":"Drilon A, Lin JJ, Filleron T, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol. 2018;13(10):1595\u2013601.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3629_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nrclinonc.2017.175","volume":"15","author":"A Drilon","year":"2017","unstructured":"Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2017;15(3):150.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"3629_CR12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.annonc.2025.06.004","volume":"36","author":"LEL Hendriks","year":"2025","unstructured":"Hendriks LEL, Cortiula F, Martins-Branco D, Mariamidze E, Popat S, Reck M. Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC Living Guideline. Ann Oncol. 2025;36(10):1223\u20137.","journal-title":"Ann Oncol"},{"issue":"5","key":"3629_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jtho.2022.12.018","volume":"18","author":"M Aldea","year":"2023","unstructured":"Aldea M, Marinello A, Duruisseaux M, et al. RET-MAP: an international multicenter study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion. J Thorac Oncol. 2023;18(5):576\u201386.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3629_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/jjco\/hyaa019","volume":"50","author":"J Lee","year":"2020","unstructured":"Lee J, Ku BM, Shim JH, et al. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. Jpn J Clin Oncol. 2020;50(5):594\u2013601.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"3629_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12885-024-11852-3","volume":"24","author":"N Yan","year":"2024","unstructured":"Yan N, Zhang H, Shen S, Guo S, Li X. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data. BMC Cancer. 2024;24(1):178.","journal-title":"BMC Cancer"},{"issue":"11","key":"3629_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2217\/imt-2021-0035","volume":"13","author":"NR Bhandari","year":"2021","unstructured":"Bhandari NR, Hess LM, Han Y, Zhu YE, Sireci AN. Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer. Immunotherapy. 2021;13(11):893\u2013904.","journal-title":"Immunotherapy"},{"issue":"11","key":"3629_CR17","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1007\/s12325-024-02983-x","volume":"41","author":"S Lu","year":"2024","unstructured":"Lu S, Shen L, Wang Q, et al. Diagnosis, treatment patterns, and outcomes in real-world patients with RET fusion-positive non-small cell lung cancer in China. Adv Ther. 2024;41(11):4248\u201365.","journal-title":"Adv Ther"},{"issue":"13","key":"3629_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","volume":"35","author":"O Gautschi","year":"2017","unstructured":"Gautschi O, Milia J, Filleron T, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the Global, Multicenter RET Registry. J Clin Oncol. 2017;35(13):1403\u201310.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3629_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383(9):813\u201324.","journal-title":"N Engl J Med"},{"issue":"15","key":"3629_CR20","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","volume":"27","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res. 2021;27(15):4160\u20137.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3629_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825\u201335.","journal-title":"N Engl J Med"},{"key":"3629_CR22","unstructured":"Eli Lilly and Co. RETEVMO\u00ae (selpercatinib) capsules, for oral use. Prescribing information: US Food and Drug Administration; Sept 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213246s011s013lbl.pdf. Accessed 1 Oct 2025."},{"issue":"20","key":"3629_CR23","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023;389(20):1839\u201350.","journal-title":"N Engl J Med"},{"issue":"21","key":"3629_CR24","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1200\/JCO.24.00724","volume":"42","author":"M Perol","year":"2024","unstructured":"Perol M, Solomon BJ, Goto K, et al. CNS protective effect of selpercatinib in first-line RET fusion-positive advanced non-small cell lung cancer. J Clin Oncol. 2024;42(21):2500\u20135.","journal-title":"J Clin Oncol"},{"key":"3629_CR25","unstructured":"Eli Lilly and Co. RETSEVMO\u00ae (selpercatinib) capsules, for oral use. Summary of product characteristics: European Medicines Agency; Jan 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/retsevmo-epar-product-information_en.pdf. Accessed 1 Oct 2025."},{"key":"3629_CR26","unstructured":"The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers [press release]. 2022. https:\/\/www.prnewswire.com\/news-releases\/the-china-nmpa-approves-selpercatinib-for-the-treatment-of-patients-with-ret-driven-lung-and-thyroid-cancers-301644366.html. Accessed 18 Dec 2024."},{"key":"3629_CR27","unstructured":"Eli Lilly Canada Inc. RETEVMO\u2122 selpercatinib capsules. Product monograph. Health Canada; Oct 2024. https:\/\/pi.lilly.com\/ca\/retevmo-ca-pm.pdf. Accessed 18 Dec 2024."},{"key":"3629_CR28","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Non-Small Cell Lung Cancer (version 3.2025\u2013January 14, 2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 2 May 2025."},{"issue":"19","key":"3629_CR29","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1182\/bloodadvances.2022009167","volume":"7","author":"J Lambert","year":"2023","unstructured":"Lambert J, Lengline E, Porcher R, Thiebaut R, Zohar S, Chevret S. Enriching single-arm clinical trials with external controls: possibilities and pitfalls. Blood Adv. 2023;7(19):5680\u201390.","journal-title":"Blood Adv"},{"issue":"5","key":"3629_CR30","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","volume":"55","author":"M Jahanshahi","year":"2021","unstructured":"Jahanshahi M, Gregg K, Davis G, et al. The use of external controls in FDA regulatory decision making. Therap Innov Regul Sci. 2021;55(5):1019\u201335.","journal-title":"Therap Innov Regul Sci"},{"key":"3629_CR31","unstructured":"CNIL. Recherches n\u2019Impliquant pas la Personne Humaine, \u00c9tudes et \u00c9valuations dans le Domaine de la Sant\u00e9. Commission Nationale de l\u2019Informatique et des Libert\u00e9s. https:\/\/www.cnil.fr\/fr\/declaration\/methodologie-de-reference-04-recherches-nimpliquant-pas-la-personne-humaine-etudes-et-evaluations-dans-le-domaine-de-la-sante. Accessed 10 Dec 2025."},{"issue":"2","key":"3629_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"3629_CR33","unstructured":"FDA Approves Lilly's Retevmo\u00ae (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type [press release]. 2022. https:\/\/investor.lilly.com\/node\/47691\/pdf. Accessed 25 July 2025."},{"issue":"11","key":"3629_CR34","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","volume":"33","author":"F Griesinger","year":"2022","unstructured":"Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022;33(11):1168\u201378.","journal-title":"Ann Oncol"},{"issue":"1","key":"3629_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30908-1","volume":"13","author":"S Popat","year":"2022","unstructured":"Popat S, Liu SV, Scheuer N, et al. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of pralsetinib in non-small cell lung cancer. Nat Commun. 2022;13(1):3500.","journal-title":"Nat Commun"},{"issue":"4","key":"3629_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100551","volume":"7","author":"C Rolfo","year":"2022","unstructured":"Rolfo C, Hess LM, Jen MH, et al. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer. ESMO Open. 2022;7(4):100551.","journal-title":"ESMO Open"},{"key":"3629_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1470387","volume":"15","author":"U Kiiskinen","year":"2025","unstructured":"Kiiskinen U, Segall G, Bailey H, Forshaw C, Puri T. Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report. Front Oncol. 2025;15:1470387.","journal-title":"Front Oncol"},{"key":"3629_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010140","author":"F De Braud","year":"2023","unstructured":"De Braud F, Deschler-Baier B, Morris JC 3rd, et al. Comparative effectiveness of first-line selpercatinib versus standard therapies in patients with RET-activated cancers: an exploratory interpatient analysis of LIBRETTO-001. Cancers (Basel). 2023;16(1):140.\u00a0","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3629_CR39","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp1003294","volume":"379","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Garassino MC. Pembrolizumab plus chemotherapy in lung cancer. N Engl J Med. 2018;379(11):e18.","journal-title":"N Engl J Med"},{"issue":"4","key":"3629_CR40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","volume":"15","author":"F Guisier","year":"2020","unstructured":"Guisier F, Dubos-Arvis C, Vinas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. J Thorac Oncol. 2020;15(4):628\u201336.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"3629_CR41","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321\u20138.","journal-title":"Ann Oncol"},{"key":"3629_CR42","unstructured":"Boehringer Ingelheim International GmbH. VARGATEF\u00ae (nintedanib) soft capsules, for oral use. Summary of product characteristics: European Medicines Agency; Aug 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vargatef-epar-product-information_en.pdf. Accessed 26 Apr 2025."},{"issue":"5","key":"3629_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14740338.2023.2224558","volume":"22","author":"AZ Al Meslamani","year":"2023","unstructured":"Al Meslamani AZ. Underreporting of adverse drug events: a look into the extent, causes, and potential solutions. Expert Opin Drug Saf. 2023;22(5):351\u20134.","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"3629_CR44","doi-asserted-by":"publisher","first-page":"S582","DOI":"10.1016\/j.jval.2024.10.3608","volume":"27","author":"S Popat","year":"2024","unstructured":"Popat S, Hochmair M, Sanchez Gasataldo A, et al. RWD50 treatment patterns and outcomes of RET fusion-positive non-small-cell lung cancer (NSCLC) patients treated with selpercatinib in Europe: interim results from the SPRINT-RET study. Value Health. 2024;27(12):S582.","journal-title":"Value Health"},{"key":"3629_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaf038","author":"NC Hogarth","year":"2025","unstructured":"Hogarth NC, Al-Kawaaz M, Linder MW. Evaluation of turnaround times and performance of in-house ChromaCode high-definition PCR compared to send-out next-generation sequencing in non-small cell lung cancer. Am J Clin Pathol. 2025;164(2):226\u201332.","journal-title":"Am J Clin Pathol"},{"key":"3629_CR46","unstructured":"European Medicines Agency. Retsevmo (selpercatinib) authorization details. April 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/retsevmo#authorisation-details. Accessed 5 Apr 2025."},{"key":"3629_CR47","unstructured":"European Medicines Agency. CHMP extension of indication variation assessment report: Retsevmo (selpercatinib). 2022. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/retsevmo-h-c-005375-ii-0011-epar-assessment-report-variation_en.pdf. Accessed 5 Mar 2025."},{"issue":"24","key":"3629_CR48","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1002\/cncr.34926","volume":"130","author":"S Roy-Chowdhuri","year":"2024","unstructured":"Roy-Chowdhuri S, Mani H, Fox AH, et al. The American Cancer Society National Lung Cancer Roundtable strategic plan: methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer. Cancer. 2024;130(24):4200\u201312.","journal-title":"Cancer"},{"issue":"3","key":"3629_CR49","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/curroncol31030115","volume":"31","author":"KE Fleming","year":"2024","unstructured":"Fleming KE, Hupel A, Mithoowani H, Lulic-Kuryllo T, Valdes M. Biomarker turnaround times and impact on treatment decisions in patients with advanced non-small cell lung carcinoma at a large Canadian community hospital with an affiliated regional cancer centre. Curr Oncol. 2024;31(3):1515\u201328.","journal-title":"Curr Oncol"},{"issue":"2","key":"3629_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.22.00393","volume":"41","author":"A Drilon","year":"2023","unstructured":"Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase\u00a0I\/II trial. J Clin Oncol. 2023;41(2):385\u201394.","journal-title":"J Clin Oncol"},{"key":"3629_CR51","doi-asserted-by":"crossref","unstructured":"Passiglia F, Listi A, Bironzo P, et al. Actionable NSCLC mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA). J Thorac Oncol. 2025;20(5):614\u201324.","DOI":"10.1016\/j.jtho.2024.12.010"},{"issue":"22","key":"3629_CR52","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3390\/cancers16223835","volume":"16","author":"C-Y Liao","year":"2024","unstructured":"Liao C-Y, Gonzalez-Ferrer C, Whipple S, et al. Real-world outcomes of selective RET inhibitor selpercatinib in the United States: descriptive, retrospective findings from two databases. Cancers (Basel). 2024;16(22):3835.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3629_CR53","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jtho.2023.01.008","volume":"18","author":"YR Murciano-Goroff","year":"2023","unstructured":"Murciano-Goroff YR, Falcon CJ, Lin ST, et al. Central nervous system disease in patients with RET fusion-positive NSCLC treated with selpercatinib. J Thorac Oncol. 2023;18(5):620\u20137.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3629_CR54","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00432-022-03959-6","volume":"149","author":"G Wu","year":"2023","unstructured":"Wu G, Guo L, Gu Y, et al. The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients. J Cancer Res Clin Oncol. 2023;149(3):1019\u201328.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"3629_CR55","doi-asserted-by":"publisher","first-page":"S357","DOI":"10.1016\/j.jtho.2023.09.628","volume":"18","author":"O Arrieta","year":"2023","unstructured":"Arrieta O, Cardona A, Cordeiro de Lima VC, et al. P2.10-13 characteristics and outcomes of Hispanic patients with RET-Fusion positive NSCLC treated in real-world practice. J Thorac Oncol. 2023;18(11):S357\u20138.","journal-title":"J Thorac Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03629-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03629-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03629-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:11:08Z","timestamp":1785517868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03629-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3629"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03629-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luis Le\u00f3n-Mateos has received grants or contracts from the Spanish Society for Medical Oncology 2024; consulting fees from Eli Lilly, BeOne, AstraZeneca, MSD, and Pfizer; payment or honoraria from AstraZeneca, Regeneron, Janssen, Pfizer, Takeda, and BMS; and support for attending meetings and\/or travel from Janssen, Pfizer, and AstraZeneca. Maximillian J. Hochmair has received consulting fees from Boehringer, AstraZeneca, MSD, and Roche; and payment or honoraria from AstraZeneca, Eli Lilly, Janssen, Pfizer, Takeda, and MSD. Jean-Bernard Auliac has received consulting fees from AstraZeneca, Regeneron, and Amgen; payment or honoraria from BMS, Takeda, and Johnson and Johnson; and support for attending meetings and\/or travel from PharmaMar, Sanofi, and AstraZeneca. Damian T Rieke has received consulting fees from BeiGene and TheraMe; payment or honoraria from Eli Lilly, BMS, Roche, and Bayer; support for attending meetings and\/or travel from Johnson and Johnson, and Bayer; and has received equipment, materials, drugs, medical writing, gifts or other services from Seagen. Patricia Iranzo Gomez has received consulting fees from Boehringer; payment or honoraria from AstraZeneca, Regeneron, Janssen, Pfizer, and Takeda; and support for attending meetings and\/or travel from Janssen, Merck, and AstraZeneca. Tarun Puri, Ana Sofia Afonso, Manoj Khanal, Xiaohong (Ivy) Li, and Grace Segall are employees and minor shareholders (with stock or stock options) of Eli Lilly and Company. Amparo S\u00e1nchez-Gastaldo, Audrey Rabeau, and Teresa Mor\u00e1n have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki, and consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations of the countries where the study was conducted. Since this was an observational study with no protocol-mandated intervention, the assessment and treatment of the patients were based solely on the investigator\u2019s routine or usual practice in the provision of care to patients with advanced stages of cancer. Informed consent waivers were requested during ethical review processes in each site and country: a full waiver was obtained for Austria (Ethikkommission der Stadt Wien; approval no. EK 23-037-VK), and partial waivers for Germany (Ethikkommission \u2013 Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin; approval no. EA2\/002\/23) and Spain (Comit\u00e9 de Etica de la Investigaci\u00f3n con Medicamentos de Galicia; approval no. 2022\/495). Signed informed consent from patients was obtained in the event that a waiver was not obtained. In France, since this was a noninterventional health study not involving human participants that used existing data for a public-health purpose, the study was conducted under Commission Nationale de L\u2019informatique et des Libert\u00e9s Reference Methodology 004 (registration no. 2219942) [\n                      \n                      ]. In accordance with this framework, ethics committee approval was not required; instead, patients received prior written information about the study with the option to opt out, and a formal declaration of compliance was released by the sponsor.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}